Oppenheimer Issues Pessimistic Forecast for Keros Therapeutics (NASDAQ:KROS) Stock Price

Keros Therapeutics (NASDAQ:KROS - Free Report) had its price target trimmed by Oppenheimer from $102.00 to $63.00 in a research note issued to investors on Monday, MarketBeat Ratings reports. The brokerage currently has an outperform rating on the stock.

Several other research analysts have also recently issued reports on KROS. William Blair cut Keros Therapeutics from an "outperform" rating to a "market perform" rating in a research report on Thursday. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Keros Therapeutics in a report on Friday, November 22nd. Bank of America lowered their target price on shares of Keros Therapeutics from $81.00 to $76.00 and set a "buy" rating for the company in a report on Thursday, September 12th. Scotiabank reduced their price objective on shares of Keros Therapeutics from $77.00 to $44.00 and set a "sector outperform" rating for the company in a research report on Friday. Finally, TD Cowen cut shares of Keros Therapeutics from a "buy" rating to a "hold" rating in a research report on Thursday. Four research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $81.33.

Keros Therapeutics Stock Up 3.1 %

KROS stock traded up $0.59 during midday trading on Monday, reaching $19.42. 2,200,323 shares of the company's stock traded hands, compared to its average volume of 464,405. The firm's fifty day moving average price is $59.11 and its 200-day moving average price is $52.69. Keros Therapeutics has a 52 week low of $15.67 and a 52 week high of $73.00. The company has a market cap of $786.65 million, a price-to-earnings ratio of -3.61 and a beta of 1.20.

Keros Therapeutics (NASDAQ:KROS - Get Free Report) last posted its earnings results on Wednesday, November 6th. The company reported ($1.41) EPS for the quarter, missing the consensus estimate of ($1.28) by ($0.13). The business had revenue of $0.39 million for the quarter. Keros Therapeutics had a negative return on equity of 41.74% and a negative net margin of 27,890.94%. Keros Therapeutics's quarterly revenue was up 4750.0% compared to the same quarter last year. During the same period in the previous year, the firm posted ($1.33) earnings per share. Analysts forecast that Keros Therapeutics will post -5.26 earnings per share for the current year.

Institutional Trading of Keros Therapeutics

Several hedge funds have recently made changes to their positions in KROS. KBC Group NV increased its holdings in Keros Therapeutics by 52.0% in the 3rd quarter. KBC Group NV now owns 1,263 shares of the company's stock worth $73,000 after acquiring an additional 432 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. increased its position in shares of Keros Therapeutics by 26.0% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,357 shares of the company's stock valued at $77,000 after buying an additional 280 shares during the period. Values First Advisors Inc. purchased a new stake in shares of Keros Therapeutics in the third quarter worth about $89,000. Point72 Asia Singapore Pte. Ltd. bought a new position in shares of Keros Therapeutics in the second quarter valued at approximately $128,000. Finally, LMR Partners LLP bought a new stake in Keros Therapeutics during the third quarter valued at $213,000. 71.56% of the stock is currently owned by institutional investors.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.